Biogen
A common measure of a stock’s relative value is the multiple of its price to estimated earnings per share. At its current price of $226 a share, Biogen is trading at a multiple of about eight times earnings. It will take a decline of about 10 percent to put Biogen in the bargain bin.
“Everyone is trying to understand where the floor is,” said Suneja, the Guggenheim analyst.
That could take a while. Like I said, not for the faint of heart.
https://www.bostonglobe.com/business/201...story.html
A common measure of a stock’s relative value is the multiple of its price to estimated earnings per share. At its current price of $226 a share, Biogen is trading at a multiple of about eight times earnings. It will take a decline of about 10 percent to put Biogen in the bargain bin.
“Everyone is trying to understand where the floor is,” said Suneja, the Guggenheim analyst.
That could take a while. Like I said, not for the faint of heart.
https://www.bostonglobe.com/business/201...story.html